<DOC>
	<DOCNO>NCT01153880</DOCNO>
	<brief_summary>Retapamulin , topical pleuromutilin antibiotic , first new class topical antibiotic approve human use . In United States ( US ) , retapamulin approve treatment impetigo person nine month age launch 12 April 2007 . This five-year study design examine use retapamulin pediatric population less nine month age . We conduct annual assessment prescription sale claim retapamulin use Integrated Health Care Information Services ( IHCIS ) National Managed Care Benchmarked Database . For year reporting , observed frequency exposure , without same-day , co-prescribed sale claim mupirocin , identify . The study objectives determine frequency retapamulin sale representative US population stratify designated age group determine frequency same-day sale topical agent , mupirocin .</brief_summary>
	<brief_title>United States Pharmacovigilence Retapamulin-Prescribing</brief_title>
	<detailed_description>The IHCIS Health Insurance Portability Accountability Act ( HIPAA ) compliant encrypt member provider identifier ; date birth restrict year birth . Based year birth prescription sale claim date , age time prescription ( ) categorize less 9 month ( definitive ) less 9 month ( uncertain ) .</detailed_description>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Mupirocin</mesh_term>
	<criteria>The study population consist 'eligible member ' IHCIS database valid gender age record least 1 month enrolment eligibility pharmacy benefit . Membership IHCIS without valid gender age record , enrolment le 1 month , ineligibility pharmacy benefit exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Altabax</keyword>
	<keyword>United States</keyword>
	<keyword>topical</keyword>
	<keyword>Mupirocin</keyword>
	<keyword>Retapamulin</keyword>
	<keyword>Bactroban</keyword>
</DOC>